Mono-and disubstituted novel derivatives of the heptaene nystatin analog 28,29-didehydronystatin A 1 (S44HP, 1) were obtained by chemical modification of the exocyclic C-16 carboxyl and/or an amino group of mycosamine moiety. The strategy of preparation of mono-and double-modified polyene macrolides was based on the use of intermediate hydrophobic N-Fmoc (9-fluorenylmethoxycarbonyl) derivatives that facilitated the procedures of isolation and purification of new compounds. The antifungal activity of the new derivatives was first tested in vitro against yeasts and filamentous fungi, allowing the selection of the most active compounds that were subsequently tested for acute toxicity in mice. 2-(N,N-dimethylamino)ethylamide of 1 (2) and 2-(N,N-dimethylamino)ethylamide of N-fructopyranosyl-28,29-didehydronystatin A 1 (2a) were then selected for further evaluation in a mouse model of disseminated candidosis, and showed high efficacy while being considerably less toxic than amphotericin B (AmB). The compound with improved water solubility (2G, L-glutamic acid salt of 2) showed better chemotherapeutic activity than AmB in the mouse model of candidosis sepsis on a leucopenic background. Very low antifungal effect was seen after treatment with AmB, even if it was used in maximum tolerated dose (2 mg kg À1 ). Unlike AmB, compound 2G exhibited high activity in doses from 0.4 up to 4.0 mg kg À1 , despite leucopenic conditions.
INTRODUCTION
Systemic fungal infections are becoming increasingly common in modern hospitals. Approximately 40% of deaths from nosocomial infections are caused by fungi, and 80% of these are caused by species of Candida and Aspergillus. The frequency of invasive fungal infections has increased with the rise in the number of immunocompromised patients (by disease or because of the use of immunosuppressive agents). 1 Patients with AIDS caused by human immunodeficiency virus infection, low birthweight infants, neutropenic patients receiving chemotherapy and oncology patients with immune suppression are at an increased risk for invasive fungal infections.
Polyene macrolide amphotericin B (AmB) is the first-line therapy for systemic infection because of its broad spectrum and fungicidal activity. The mechanism of fungicidal action of polyene macriolides is attributed to their binding to ergosterol in the fungal cell membrane, which leads to formation of pores and leakage of ions, resulting in fungal cell death. 2 However, considerable side effects limit the clinical utility of AmB. Therefore, there is an urgent need to develop new antifungal antibiotics that are efficacious and devoid of toxicity.
Earlier, it was shown that double modifications of polyene macrolides AmB [3] [4] [5] or partricin A 6 improve the biological properties of parent antibiotics. For example, N-(1-piperidinepropyl)amphotericin B methyl ester (PAME) was described as a new derivative of AmB with reduced toxicity. 3 The new semisynthetic derivative of partricin A, SPA-S-753/SPK-843 (N-dimethylaminoacetyl-partricin A 2-dimethylaminoethylamide diascorbate salt), has shown a much higher therapeutic activity and better pharmacological properties than the lipid formulation of AmB, and this agent has reached the clinical stage. 6 Recently, a novel genetically engineered antifungal heptaene nystatin analog, 28,29-didehydronystatin A 1 (S44HP) 7 (see structure 1 on Scheme 1), was used as a scaffold for chemical modification. 8 Synthesis and structure-activity relationship of 23 new derivatives of 1 modified on the C16-COOH or the C3¢-NH 2 group have been reported. 8 3-(N,N-dimethylamino)propylamide (DMAP-amide) of 28,29-didehydronystatin A 1 (3) (Scheme 1) showed the best biological properties. 8 The in vitro antifungal activities of DMAP-amide against four tested fungal strains were comparable with those of AmB and 1, but the in vivo studies clearly showed superior pharmacological properties of this derivative over AmB. 8 The marked antifungal activity shown by a number of 28,29-didehydronystatin A 1 derivatives and particularly by the DMAPamide of 28,29-didehydronystatin A 1 (3) promoted a further structural modification study in our laboratory. On the basis of previously obtained structure-activity relationships, we designed and synthesized derivatives of 1, substituted both at the carboxyl and amino groups, and studied their antifungal activity. The most active compounds were subsequently tested for acute toxicity in mice. High activity and low toxicity of the new compounds, 2-(N,N-dimethylamino)ethylamide of 28,29-didehydronystatin A 1 (2) and 2-(N,N-dimethylamino) ethylamide of N-fructopyranosyl-28,29-didehydronystatin A 1 (2a), prompted us to study the antifungal activity of the water-soluble salt of 2 (2G) in the model of candidosis sepsis in leucopenic mice.
O

RESULTS
Chemistry
The N-9-fluorenylmethoxycarbonyl (N-Fmoc) derivative of 1 was used as a key compound in the synthesis of amides 2-(N,N-dimethylamino)ethylamide (DMAE-amide) (2), DMAP-amide (3) and 3-hydroxypropylamide (4). 8 The corresponding N-Fmoc derivatives of amides 2-4 were purified by column chromatography and deprotected, resulting in amides 2-4 with high purity.
Starting from amides 2 to 4, the following new double-modified derivatives of 1 were obtained: (1) ketosyl derivatives 2a, 2b, 3a, 3b and 4a (products of the Amadori rearrangement of N-glycosylderivatives of amides); (2) N-alkyl derivatives 2c-4c; and (3) N-aminoacyl derivatives 3d, 2e-4e. The DMAE amide of N-fructopyranosyl-28,29-didehydronystatin A 1 (2a), the DMAP-amide of N-fructopyranosyl-28,29-didehydronystatin A 1 (3a), the 3-hydroxypropylamide of N-fructopyranosyl-28,29-didehydronystatin A 1 (4a), the DMAEamide of N-tagatopyranosyl-28,29-didehydronystatin A 1 (2b) and the DMAP-amide of N-tagatopyranosyl-28,29-didehydronystatin A 1 (3b) were obtained starting from the corresponding amides 2-4 and Dglucose or D-galactose according to the procedure described by Preobrazhenskaya et al. 8 4-(N,N-dimethylamino)benzyl derivatives 2c, 3c and 4c of amides 2-4 were prepared starting from the corresponding amides 2-4 and 4-(N,N-dimethylamino)benzaldehyde. N-L-lysyl derivative 3d of amide 3 was obtained by acylation reaction starting from amide 3 and N-Fmoc-L-lysine in the presence of coupling reagent benzotriazol-1-yloxytripyrrolidino-phosphonium hexafluorophosphate (PyBOP). Deprotection of the intermediate NFmoc-L-lysyl derivative of 3 resulted in 3d. N-(N,N-dimethylglycyl) derivatives 2e-4e of the corresponding amides 2-4 were obtained by the acylation reaction starting from amides 2-4 and N,N-dimethylglycine in the presence of coupling reagent PyBOP. The L-glutamate salt of 2 (2G) was prepared to improve water solubility.
N-Fmoc-protected derivatives of 5 and 6 were used as key compounds in the other approach of the synthesis of disubstituted derivatives (Scheme 2). Acylation of 1 with 4-(N-Fmoc-aminomethyl)benzoic acid in the presence of PyBOP or with N-Fmoc-Llysine in the presence of dicyclohexylcarbodiimide/hydroxybenzotriazole resulted in the corresponding N-Fmoc-aminoacyl derivatives of 1. These intermediates were also transformed into the corresponding N-Fmoc-aminoacyl-28,29-didehydronystatin A 1 DMAE-amide, DMAP-amide and 3-hydroxypropylamide, and purified by column chromatography. The target compounds N-L-lysyl (2d or 4d) and N-(4-aminomethyl)benzoyl derivatives (2f-4f) were isolated after removing the protecting Fmoc group in the presence of piperidine in dimethylsulfoxide (DMSO) (Scheme 2, Table 1 Synthesis of N-L-lysyl derivative (6) was described earlier in Preobrazhenskaya et al. 8 The structures of obtained compounds were confirmed by high-resolution mass spectrometry (Table 1) and nuclear magnetic resonance (NMR) spectroscopy (supplementary material).
Biological testing
Activity of the 19 new derivatives of 1 compared with AmB, parent antibiotic 1 and the earlier obtained amides 3, 4 and N-L-lysyl derivative (6) in in vitro tests against yeasts Candida albicans and Cryptococcus humicolus and filamentous fungi (molds) Aspergillus niger and Fusarium oxysporum was investigated. Determination of MICs was carried out as described previously in Preobrazhenskaya et al., 8 and the results are presented in Tables 2 and 3 .
Monomodified amides 3, 4 and the starting 1 were shown to have equal activity against the four investigated fungal strains. Apparently, the new monosubstituted DMAE-amide of 28,29-didehydronystatin A 1 (2) was twofold more active than 1 against all four strains. The DMAE-amide of N-fructopyranosyl-28,29-didehydronystatin A 1 (2a), the DMAP-amide of N-fructopyranosyl-28,29-didehydronystatin A 1 (3a) and the DMAE-amide of N-tagatopyranosyl-28,29-didehydronystatin A 1 (2b) were the most active compounds among the disubstituted derivatives of 1. Their activities were equal (MICs¼0.5 and 1 mg ml À1 against C. albicans and A. niger) or very close (MICs¼1 and 2 mg ml À1 against Cr. humicolus and F. oxysporum) to those of compound 2. In contrast, 3-hydroxypropylamide of N-fructopyranosyl-28,29-didehydronystatin A 1 (4a) showed lower activity against all strains: MICs¼4 for C. albicans, Cr. humicolus and A. niger, and 16 mg ml À1 for F. oxysporum.
The activities of 4-(N,N-dimethylamino)benzyl amides 2c, 3c and 4c or of N,N-dimethylglycylamides 2e, 3e and 4e were very similar to those of 1 or of amides 3 and 4 (MICsB1-2 mg ml À1 ) for three strains (C. albicans, Cr. humicolus and A. niger). However, their activities against F. oxysporum were rather low (MIC¼16 mg ml À1 ). N-(4-aminomethyl)benzoyl-28,29-didehydronystatin A 1 (5) and N-L-lysyl-28,29-didehydronystatin A 1 (6) showed low antifungal activities in vitro in comparison with the parent compound 1. It is interesting to note that the secondary modification of antibiotics (transformation of the 16-COOH group into DMAE-amide, DMAP-amide or 3-hydroxypropylamide) in the case of compound 5 (yielding compounds 2f, 3f and 4f, correspondingly) almost did not change the activity against all four strains (MICB4-16 mg ml À1 ). However, in the case of compound 6 (MICB8-16 mg ml À1 ), the same secondary modifications (compound 2d, 3d or 4d) did improve antifungal activity against all four strains (MICB1-4 mg ml À1 ).
As compounds 2 and 2a showed antifungal activities better than AmB or 1 in four tests, they were chosen for in vivo investigations.
Study of the specific activity of 2 and 2a in the mouse model of candidosis was performed as described in the experimental section and in the previous paper by Preobrazhenskaya et al. 8 The fungal load in kidneys of animals infected with C. albicans (ATCC 14053) and treated with antibiotics was determined and compared with that of untreated animals. Results are presented in Table 4 . The analysis of the results obtained revealed the dose-dependent effect of both studied compounds, and both 2 and 2a were more effective than AmB, with 2 showing the best activity in vivo. Unlike AmB, treatment using 2 or 2a in the maximum studied therapeutic doses led to the maximum effect (that is, an almost complete elimination of Candida from kidneys after 4 days of treatment). Compounds 2 and 2a were almost 10 times less toxic than AmB; for 2a, the highest effective dose was equal to 6% and for 2, it was 2% of the maximum tolerated dose (MTD), whereas AmB had an effective dose equal to 62% of MTD.
Compound 2 showed the best results in this model and it prompted us to prepare water-soluble L-glutamate salt of compound 2 (2G) for the next step of investigations. The antifungal activity of 2G was very close to the activity of 2 and AmB in four in vitro tests against C. albicans, Cr. humicolus, A. niger and F. oxysporum.
Acute toxicity of compounds 2 and 2G was studied as described previously in Preobrazhenskaya et al. 8 MTD and LD 50 values for 2 are 25.9 (24.6C27.2) mg kg À1 and 32.2 (28.8C35.7) mg kg À1 , and for 2G, 14.7(12.8C16.8) mg kg À1 and 22.1 (19.3C24.9) mg kg À1 , respectively. High solubility and wide therapeutic window (MTD-LD 50 dose interval) of compound 2G permitted us to consider it for further investigation in subchronical study.
The multiple-dose toxicity of 2G and AmB in male Wistar rats was compared. The animals received AmB or 2G i.v. at a daily dose of 0.1 and 0.2 MTD seven times with 48-h intervals. Total doses were equal to MTD and LD 50 . Compound 2G showed less pronounced nephrotoxicity and did not influence the quantity of red blood cells and the level of hemoglobin in peripheral blood. The last fact indicates that 2G has no hemolytic properties. The absence of hemolytic activity was confirmed by microscopic pathology observations, as no significant increase in hemosiderin was observed in the spleen of animals treated with 2G.
To investigate the in vivo efficacy of 2G, a model of candidosis sepsis in leucopenic mice (cyclophosphamide-induced) was used. Leucopenia in animals, induced by cyclophosphamide, is one of the immunosuppression models. For these mice, we adapted the technical procedure described in Takemoto et al. 9 A very low antifungal effect was seen after the treatment with AmB, even if the antibiotic was used 
DISCUSSION
Chemical modification of polyene macrolide antibiotics leads to serious problems that stem from the high molecular weight of these compounds, their poor solubility in common organic solvents, as well as their high chemo-and photosensitivities and formation of aggregates that seriously hamper the processes of isolation and purification. Our synthetic strategy was based on the use of intermediate polyene derivatives containing a hydrophobic protecting group that increases the stability and facilitates column chromatographic purification of these compounds. We selected the Fmoc protecting group, as this type of derivatization led to the formation of polyene derivatives suitable for purification, and de-blocking conditions were not harmful for the antibiotic structure. The in vitro experiments showed high activities (MICB 1-2 mg ml À1 ) against C. albicans, Cr. humicolus and A. niger and moderate activities against F. oxysporum (MICB4-16 mg ml À1 ) (Tables 2 and 3 ) for all disubstituted derivatives of 1. The monosubstituted derivative 2 and the disubstituted derivatives 2a and 2b were the best in in vitro tests. Compounds 2 and 2a were chosen for in vivo experiments.
It was shown that 2 and 2a were clearly superior to AmB in terms of both toxicity and therapeutic efficacy in mouse models (Table 4) .
We also compared antifungal activities and toxicity properties of derivatives with very close chemical structures-compounds 2 and 3. The MTD-LD 50 dose interval for 2 (MTD¼25.9 (24.6C27.2) mg kg À1 and LD 50 ¼32.2 (28.8C35.7) mg kg À1 ) ( Table 4 ) was slightly better than that for 3 (MTD¼11.9 (10.3C13.6) mg kg À1 and LD 50 ¼16.4 (13.9C18.9) mg kg À1 ). 8 The differences in toxicity and antifungal activity for compounds 2 and 3 can be explained by the difference in their chemical structure.
Derivative 2 and its water-soluble L-glutamate salt 2G showed equal in vitro activities against four tested strains. The model of candidosis sepsis in leucopenic mice (cyclophosphamide-induced) was used to investigate the in vivo efficacy of 2G. It is important to mention that systemic fungal infections are especially dangerous for patients whose immune system is compromised. It was shown that 2G was clearly superior to AmB in terms of both toxicity and therapeutic efficacy in mouse models (Figure 1) .
The MTD-LD 50 dose interval for water-soluble 2G (MTD¼ 14.7(12.8C16.8) mg kg À1 and LD 50 ¼22.1 (19.3C24.9) mg kg À1 ) was slightly better in comparison with compound 2.
Hence, we generated a series of new semisynthetic polyene macrolides, and demonstrated that derivatives 2, its L-glutamate salt 2G and 2a have advantages over AmB in terms of both toxicity and therapeutic efficacy in mouse models. The high solubility and wide therapeutic window of compound 2G, together with high chemotherapeutic activity in the mouse model of candidosis sepsis on a leucopenic background, give hope that we are on the way to developing a new, safe and efficient antifungal drug for human use. b HPLC was carried out on a Shimadzu HPLC instrument of the LC 10 series on a Kromasil 100-C18 column (4Â250 mm, particle size 6 mm) at an injection volume of 20 ml and a wavelength of 408 nm with a flow rate of 1.0 ml min À1 . The system compared 0.2% HCOONH 4 (pH 4.5) with acetonitrile. The proportion of acetonitrile was varied from 30% to 70 % for 30 min (system A); from 25% to 65% for 40 min (system B); from 30% to 90% for 30 min (system C); isocratic system-35 % of acetonitrile (system D 
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METHODS
General experimental procedures
Polyene macrolide 1 was produced and purified as described in Preobrazhenskaya et al. 8 Spots were detected by sight and by using a UV lamp at 254 nm. HPLC was carried out on a Shimadzu HPLC instrument (Shimadzu, Kyoto, Japan) of the LC 10 series (Shimadzu) on a Kromasil 100-C18 column (Kromasil; 4Â250 mm, particle size, 6 mm) at an injection volume of 20 ml (concentration of samples was 0.02-0.03 mg ml À1 ) and at a wavelength of 408 nm with a flow rate of 1.0 ml min À1 . The system compared 0.2% HCOONH 4 (pH 4.5) with acetonitrile. The proportion of acetonitrile varied from 30 to 70% for 30 min (system A); from 25 to 65% for 40 min (system B); from 30 to 90% for 30 min (system C); isocratic system-35% of acetonitrile (system D). 1 H-NMR spectra were recorded on a Varian VXR-400 NMR spectrometer (Varian, Palo Alto, CA, USA) at 351C and referenced to TMS, observing protons at 400 Mhz. Mass spectra determined by matrix-assisted laser desorption/ionization (MALDI) were recorded on Brucker BIFLEX III (Brucker, Bremen, Germany). Data for the predominant monoisotope peak are presented. All solutions were dried over sodium sulfate and evaporated at reduced pressure on a Buchi rotary evaporator (Buchi, Flawil, Switzerland) at a temperature below 351C. Amide 2 (200 mg, 0.2 mmol) was dissolved in DMSO (5 ml) and the solution of L-glutamic acid (29.4 mg, 0.2 mmol) in H 2 O (2 ml) was added. The mixture was kept at room temperature for 15 min. Addition of diethyl ether (6 ml) to the mixture led to an oily residue, which was shaken successively with diethyl ether (3Â6 ml). After addition of 10 ml of acetone to this oil, a yellow precipitate of salt was formed. The precipitate was filtrated, washed by acetone and then dried in vacuo, yielding 210 mg of 2G (yield 92%, purity 97.8%, R t ¼10.48, system A).
N-ketosyl derivatives (products of Amadori rearrangement) of amides (2a, 2b, 3a, 3b and 4a)
All derivatives were obtained as per the method described in Preobrazhenskaya et al., 8 starting from the corresponding amide 2, 3 or 4 (0.1 mmol) and a monosaccharide (D-glucose or D-galactose) (0.8 mmol) in dimethylformamide. The obtained crude compounds 2a, 2b, 3a, 3b and 4a were purified by column chromatography on Sephadex G-25 (Pharmacia Fine Chemicals AB, Uppsala, Sweden). Column chromatography was carried out using water. The purity of the fraction was controlled by TLC (system III). Fractions containing the desired compound were collected and the solution was concentrated. The addition of acetone resulted in a yellow precipitate, which was filtered off, washed with acetone and dried in vacuo. The compound 2a was obtained as a hydrochloride by adding 0.1N HCl/methanol at pH B4 to the solution of 2a in methanol. The addition of diethyl ether resulted in a yellow precipitate, which was filtered off, washed with diethyl ether and dried in vacuo. The yields of pure compounds 2a, 2b, 3a, 3b and 4a were about 30-40%.
N-alkyl derivatives of amides of 1 (2c, 3c and 4c)
N-alkyl derivatives were obtained according to the method described by Preobrazhenskaya et al., 8 starting from the appropriate amide 2, 3 or 4 (0.1 mmol), 4-(N,N-dimethylamino)benzaldehyde (0.4 mmol) and NaBH 3 CN (0.4 mmol) in dimethylformamide. The yields of pure compounds 2c, 3c and 4c were about 50-60%.
N-L-lysyl-N,N-dimethylaminopropyl amide of 1 (3d)
To a solution of amide 3 (50 mg, 0.05 mmol) in DMSO (1 ml), N a ,N e -di-Fmoc-L-lysine (60 mg, 0.1 mmol) and Et 3 N were added (pH 7), after which PyBOP (39 mg, 0.075 mmol) was added to this mixture for 15 min. The reaction mixture was stirred at room temperature for 1 h. Subsequent addition of diethyl ether (B5 ml) to the reaction mixture led to an oily residue, which was shaken successively with diethyl ether (5 mlÂ2). After the addition of 5 ml of acetone to this oil, a yellow precipitate of amide was formed. The precipitate was filtrated, washed with acetone and then dried in vacuo yielding 50 mg N-(N a ,N e -di-Fmoc-L-lysyl)-N,N-dimethylaminopropyl amide of 1 with a purity of 95%, on the basis of HPLC data (R t ¼22.01, system B). The removal of Fmoc groups was carried out according to the method described in Preobrazhenskaya et al. 8 for N-aminoacyl derivative using the excess of piperidine in DMSO yielding the target product 3d (38 mg, 60%).
N-aminoacyl derivatives of amides of 1 (2e, 3e and 4e)
Derivatives were synthesized starting from the corresponding amides 2, 3 or 4 (0.05 mmol), N,N-dimethylglycine (0.1 mmol) and PyBOP (0.075 mmol) in DMSO as described above for 3d, and a yield of about 60-70% was obtained.
N-aminoacyl derivatives of amides of 1 (2d, 4d) Amides of N-4-aminomethylbenzoyl-28,29-didehydronystatin A 1 (2f, 3f and 4f)
To a solution of 4-(N-Fmoc-aminomethyl)benzoic acid (246 mg, 0.66 mmol) and 1 (300 mg, 0.33 mmol) in DMSO (10 ml), Et 3 N (to adjust pH 7) and PyBOP (206 mg, 0.396 mmol) were added. The reaction mixture was kept at room temperature for 6 h and then added dropwise to diethyl ether (200 ml).
The yellow precipitate was filtered off and purified by column chromatography on Merck Silica Gel (0.040-0.063 mm; Merck) in the solvent system CHCl 3 :MeOH:HCOOH (3:1:0.01) to yield N-(4-N-Fmoc-aminomethyl)benzoyl-28,29-didehydronystatin A 1 (130 mg, 31%) with a purity of 95% by HPLC data (R t ¼18.18, system B) and TLC data (R F ¼0.61, system I). Amidation of N-(4-N-Fmoc-aminomethyl)benzoyl-28,29-didehydronystatin A 1 was performed as described in Preobrazhenskaya et al. 8 (method A), 
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starting from N-(4-Fmoc-aminomethylbenzoyl)-28,29-didehydronystatin A 1 (0.03 mmol) and appropriate amine hydrochlorides (0.12 mmol) in the presence of PyBOP reagent (0.045 mmol). The reaction mixture was stirred for 7 h. HPLC data: (N,N-dimethylamino)propyl amide of N-(4-Fmoc-aminomethylbenzoyl)-28,29-didehydronystatin A 1 (R t ¼15.88, system B; R F ¼0.25, system I), hydroxypropylamide of N-(4-Fmoc-aminomethylbenzoyl)-28,29-didehydronystatin A 1 (R t ¼17.14, system B; R F ¼0.60, system I) and (N,N-dimethylamino)ethyl amide of N-(4-Fmoc-aminomethylbenzoyl)-28,29-didehydronystatin A 1 (R t ¼15.95, system B; R F ¼0.24, system I).
Deprotection was carried out according to the conditions described in Preobrazhenskaya et al., 8 yielding N-4-aminomethylbenzoyl amides 2f, 3f and 4f (yield B80%; purity 495%). 
Biology of in vivo antifungal activity
Animals. Male mice of hybrids of first generation (C57Bl/6xDBA/2)F1 B6D2F1 (weight 20-22 g), received from the Central farm 'Kryukovo' of the Russian Academy of Medical Science (RAMS, Moscow, Russia), were used. Animals were maintained in a vivarium in plastic cages (with hardwood bedding in environmentally controlled conditions: 24±11C 12 h/12 h light/ dark cycle) on a standard diet of bricketed forages with easy access to drinking water (ad libitum). After a 2-week quarantine period, healthy animals were used in experimental work.
Antifungal agents. Solutions of compounds 2, 2a or 2G were prepared 'ex tempore' and were kept in dark glass vials to avoid ingress of light. Compound 2G was dissolved in a 5% neutral sterile glucose solution. The solutions of compounds 2 and 2a were prepared as follows: Dry antibiotic substances (5 mg) were mixed with dry sodium deoxycholate (4.1 mg) in a sterile glass vial. Phosphate buffer (10 ml) (NaH 2 PO 4 , 1.59g; Na 2 HPO 4 , 0.96g; H 2 O 100 ml) was added to the mixture and the suspension was immediately subjected to vigorous shaking for 10 min until homogeneous suspensions were formed. The obtained suspensions (2 ml) were placed in new sterile glass vials, 6 ml of 5% neutral sterile glucose solution was added and the resulting solutions (0.125 mg ml À1 ) were used for i.v. administration. Preparation of the sample of AmB was also carried out in the same way.
Toxicology. Acute toxicity was studied as it was previously described by Preobrazhenskaya et al. 8 Study of specific activity of 2 and 2a on the model of candidosis sepsis of mice Study of specific activity of new polyene antibiotics on the model of candidosis sepsis in leucopenic mice Induction of temporary leucopenia. Cyclophosphamide (Biotex, Saransk, Russia) was administrated at a dose 100 mg kg À1 per day, 3 days before (d À3) and 1 day after (d 1) infection (d 0).
Animals were housed in vivariums with three mice in each cage and infected i.v. with a culture of C. albicans (strain 14053 ATCC) at a dose of 3Â10 5 CFUs per mouse in a volume of 0.1 ml. It is necessary to note that the dose of C. albicans remained constant in all experiments. The first i.v. introduction of tested preparations in corresponding doses at a volume of 0.2 ml (with a speed of 0.2 ml per 30 s) was carried out 30 min after infection.
The experiment has been planned in such a manner that, in each experiment, one dose (of AmB and of tested preparations) was used; each dose was administered daily for 4 days, from the day of infection (0, 1, 2 and 3 days). Each experiment contained a group of untreated mice, a group of mice infected with C. albicans and a group that received cyclophosphamide alone. In addition, there was a group, 'placebo' , comprised of intact (noninfected) animals, which were i.v. (in the same volume as medical preparations) injected with 0.2 ml of solvent-phosphate buffer plus 5% glucose (1:1). Placebos did not show any activity. C. albicans was never detected in noninfected animals.
After the last injection of the tested preparations, mice were weighed and killed by a cervical dislocation. Then, in sterile conditions, C. albicans burdens were determined by viable counting of homogenates from kidneys. Kidneys were removed aseptically and weighed, pounded in porcelain mortars using sterile corundum and suspensions were diluted and poured into Petri dishes containing Saburo agar. The Petri dishes were incubated for 48 h at a temperature of 35 1C, the number of colonies of C. albicans was counted and their quantity on 1 g of kidney tissue was recalculated. The first dilution was 10 -1 . Zero result at this cultivation was accepted for 5 CFUs per g.
Statistical processing was carried out with the help of the computer program Microsoft Office Excel 2003. Significant accepted distinctions had an average value of Pp0.05 when compared using Student's t criterion. Data are presented in Figure 1 .
